Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — UBS Global Healthcare Conference 2018
20 slides from Nxera Pharma's conference presentation, May 21, 2018
Slide 1: Introduction to Sosei Group
Sosei Group Corporation UBS Global Healthcare INTRODUCTION TO Conference SOSEI GROUP 21 May 2018 July 2017
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: A Japan-listed biotech with a difference
Listed 2004 in Tokyo (TSE Mothers: 4565) A Japan-listed biotech with a difference Market capitalization: c.$1.3bn Global management team Main scientific campus in the U.K. World-leader in GPCR-focused drug design based on unique IP protected StaR®1 GPCR technology & enabled SBDD2 platform Partne
Slide 4: Unique management team for a Japan-listed company
Unique management team for a Japan-listed company Significant pharma and biotech expertise Scientific Advisory Board experience Peter BAINS Dr. Malcolm WEIR Chief Executive Officer Chief R&D Officer Former Senior VP of International Commercial CEO and Co-Founder Heptares Development at GSK For
Slide 5: Why do we target G-Protein-Coupled Receptors (GPCRs)?
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Why do we target G-Protein-Coupled Receptors (GPCRs)? GPCRs are active in a wide range of disease areas Targeting a new FIC and/or improved BIC GPCR medicines ~400 ~34% 27% GPCR targets of FD
Slide 6: StaR is Revolutionary for GPCR Structure-Based Drug Design
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment StaR® is Revolutionary for GPCR Structure-Based Drug Design With a StaR® GPCR, the Structural information StaR® technology stabilizes high-tech tools of science creates better, differentiated
Slide 7: Leveraging unique GPCR technology to deliver differentiated drug candidates
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Leveraging unique GPCR technology to deliver differentiated drug candidates Partner (Traditional out-licensing / major indications) StaR®1 technology Partner + (Co-development/ GPCRs SBDD
Slide 8: Advancing a Partnered GPCR pipeline in multiple therapeutic areas
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Advancing a Partnered GPCR pipeline in multiple therapeutic areas : Current stage : Next 12–18 months progress Balanced and diversified Product/Program Modality1 Indication Partner Discovery
Slide 9: Muscarinic M1 Agonist Program for Alzheimer's disease
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Muscarinic M1 Agonist Program for Alzheimer’s disease M1 Partnered with: A novel approach for symptomatic treatment of AD HTL0018318 represents a novel approach to stimulating M1 Presynaptic
Slide 10: HTL0018318 is a potential first-in-class therapy for Alzheimer's disease
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment HTL0018318 is a potential first-in-class therapy for Alzheimer’s disease M1 Partnered with: Highly selective M1 receptor agonist derived from StaR® and SBDD Overview of the HTL0018318 muscari
Slide 11: AZD4635 has emerged as a potential next-generation I/O therapy
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment AZD4635 has emerged as a potential next-generation I/O therapy A2a Partnered with: First A2a R antagonist structurally derived from StaR® and SBDD Checkpoint inhibitors are a key cancer treat
Slide 12: AZD4635 has emerged as a potential next-generation I/O therapy
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment AZD4635 has emerged as a potential next-generation I/O therapy A2a Partnered with: First A2a R antagonist structurally derived from StaR® and SBDD Excellent clinical progress to date New supp
Slide 13: Proprietary pipeline now led by M1 DLB opportunity in Japan
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Proprietary pipeline now led by M1 DLB opportunity in Japan Focus on selected rare/orphan and specialty indications or markets Proprietary pipeline Product Modality1 Indication Originator Pha
Slide 14: HTL0018318 for DLB in Japan
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment HTL0018318 for DLB in Japan M1 DLB Great potential for M1 agonist treatment for DLB in Japan Presynaptic cholinergic Neuron DLB is the second most common form of dementia and highly releva
Slide 15: HTL0018318 for DLB in Japan: Summary of clinical program to date
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment HTL0018318 for DLB in Japan M1 DLB Summary of clinical program to date Summary of clinical progress HTL0018318 derived from Heptares’ StaR® technology and SBDD HTL0018318 - same compound
Slide 16: Strategic investment in saRNA technology
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Strategic investment in saRNA technology Exclusive option to move from 25.6% to 100% ownership at pre-determined economics Pioneering RNA activation Lead candidate CEBPA1 in Ph 1/2a for liver
Slide 17: Balance sheet strengthened to scale and progress the business
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Balance sheet strengthened to scale and progress the business Allergan upfront milestone in FY2016 drives P&L variance Summary financials (reported) Revenue (ex Allergan upfront) (JPY m)1 FY2
Slide 18: Substantial economic returns secured from lead compounds
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Substantial economic returns secured from lead compounds Provides potential source of non-dilutive finance for proprietary pipeline Summary of potential economic returns from out-licensing /
Slide 19: Global operations and aspirations – aiming to build Japan's first global biotech champion
Global operations and aspirations – aiming to build Japan’s first global biotech champion World-leader in GPCR-focused drug design based on unique IP protected StaR®1 GPCR technology & enabled SBDD2 platform Partnered clinical-stage pipeline in neurology, immuno-oncology, CNS & other diseases, w
Slide 20: Locations
Locations SOSEI GROUP HEPTARES THERAPEUTICS PMO Hanzomon 11F BioPark, Broadwater Road 2-1 Kojimachi, Chiyoda-ku Welwyn Garden City Tokyo 102-0083 Japan Hertfordshire AL7 3AX United Kingdom Grabenstrasse 11a, CH-8952 Schlieren Zürich, Switzerland www.sosei.com www.heptares.com 20 CEBPA - C Enhancing